Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down ...

Adaptimmune Therapeutics announced structural changes, including the resignation of two UK-based executives, as part of its ongoing restructuring efforts. The company plans to focus more ...

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down ...

If a candidate is developed by one company only, the appropriate licences will become exclusive to the continuing party. Aside from the upfront payment, Adaptimmune will get milestone payments of ...

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Philadelphia, Pennsylvania and Oxford, United ...

SEC Filings provided by EDGAR Online, Inc.